RxDoctor Payments Data

John Scrocco, MD

Cardiovascular Disease · Poland, OHNPI 1245350784

Payments from drug & device makers

$702in general payments, 2019–2025

Across 54 payments — averaging $13.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$189
  • Amgen$82
  • Pfizer$66
  • Cardiofocus, Inc.$57
  • Astellas Pharma US Inc$50
  • AstraZeneca$43
  • plus $215 from 9 others

What the payments were for

  • Food & beverage$67496%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$702 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$181,783
Medicare patients
2,032
Services billed
4,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban404$358,904
VyndamaxTafamidis12$273,347
EntrestoSacubitril/Valsartan162$181,167
XareltoRivaroxaban48$65,551
JardianceEmpagliflozin53$52,667
BrilintaTicagrelor50$32,220
Repatha SureclickEvolocumab11$10,552
Metoprolol Succinate569$6,896
Ranolazine ErRanolazine22$4,636
Diltiazem 24hr Er (Cd)Diltiazem Hcl129$3,712
Digoxin35$1,974
Isosorbide Mononitrate ErIsosorbide Mononitrate154$1,716
Amiodarone Hcl61$1,547
Bumetanide74$1,431
Eplerenone11$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$66$632,251416 claims
NovartisEntresto$40$181,167162 claims
Johnson & JohnsonXarelto$29$65,55148 claims
Boehringer IngelheimJardiance$28$52,66753 claims
AstraZenecaBrilinta$43$32,22050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Poland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →